Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Microb Drug Resist ; 15(3): 201-4, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19728778

RESUMO

Antibiotic-resistant Streptococcus pneumoniae (Sp) are described around the world. The present national surveillance study report analyzes more than 6000 Sp strains, isolated from adults across France in 2001 and 2003, from blood cultures (3086 in 2001 and 3164 in 2003), cerebrospinal fluid (respectively, 238 and 240), or middle ear fluid (respectively, 110 and 100). The proportion of isolates with reduced susceptibility to penicillin fell significantly between 2001 and 2003 from 46.5% to 43.9%. The proportion of high-level resistant strains to penicillin minimal inhibitory concentrations (MIC > 1 mg/L), amoxicillin, and cefotaxime (MIC > 2 mg/L) slightly decreased but remained low: 10.6%, 1.2%, and 0.2% in 2003. Resistance to other antibiotics (erythromycin, cotrimoxazole, tetracycline, and chloramphenicol) also decreased. Decrease in prevalence of penicillin-resistant Sp varied according to specimen source. The proportion of penicillin nonsusceptible pneumococci decreased in blood cultures and middle ear fluids between 2001 and 2003 but increased in cerebrospinal fluid (43.4% and 46.5%, respectively). Serotypes covered by the heptavalent vaccine accounted for 42.4% of all isolates recovered in 2001 and 46.1% in 2003. Prevalence of antibiotic-resistant Sp decreased in 2003 in France.


Assuntos
Antibacterianos/farmacologia , Farmacorresistência Bacteriana , Infecções Pneumocócicas/epidemiologia , Streptococcus pneumoniae/classificação , Streptococcus pneumoniae/efeitos dos fármacos , Adulto , Sangue/microbiologia , Líquido Cefalorraquidiano/microbiologia , Meios de Cultura , França/epidemiologia , Humanos , Testes de Sensibilidade Microbiana , Otite Média com Derrame/microbiologia , Infecções Pneumocócicas/microbiologia , Vigilância da População , Prevalência , Sorotipagem , Streptococcus pneumoniae/isolamento & purificação
2.
Antimicrob Agents Chemother ; 51(4): 1304-9, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17220412

RESUMO

Two clinical isolates of Escherichia coli, CF1179 and CF1295, were isolated from a patient hospitalized in the hematology unit of the University Hospital of Clermont-Ferrand, Clermont-Ferrand, France. They were resistant to penicillin-clavulanate combinations and to ceftazidime. The double-disk synergy test was positive only for isolate CF1179. Molecular comparison of the isolates showed that they were clonally related. E. coli recombinant strains exhibiting the resistance phenotype of the clinical strains were obtained by cloning. The clones corresponding to strains CF1179 and CF1295 produced TEM-type beta-lactamases with pI values of 5.7 and 5.3, respectively. Sequencing analysis revealed two novel blaTEM genes encoding closely related complex mutant TEM enzymes, designated TEM-151 (pI 5.3) and TEM-152 (pI 5.7). These two genes also harbored a new promoter region which presented a 9-bp deletion. The two novel beta-lactamases differed from the parental enzyme, TEM-1, by the substitution Arg164His, previously observed in extended-spectrum beta-lactamases (ESBLs), and by the substitutions Met69Val and Asn276Asp, previously observed in the inhibitor-resistant penicillinase TEM-36/IRT-7. They differed by two amino acid substitutions: TEM-152 harbored a Glu240Lys ESBL-type substitution and TEM-151 had an Ala284Gly substitution. Functional analysis of TEM-151 and TEM-152 showed that both enzymes had hydrolytic activity against ceftazidime (kcat, 5 and 16 s-1, respectively). TEM-152 was more resistant than TEM-151 to the inhibitor clavulanic acid (50% inhibitory concentrations, 1 versus 0.17 microM). These results confirm the evolution of TEM-type enzymes toward complex enzymes harboring the two kinds of substitutions which confer an extended spectrum of action against beta-lactam antibiotics and resistance to inhibitors.


Assuntos
Farmacorresistência Bacteriana/genética , Escherichia coli/efeitos dos fármacos , Mutação , beta-Lactamases/genética , Escherichia coli/enzimologia , Escherichia coli/genética , Evolução Molecular , Humanos , Testes de Sensibilidade Microbiana , Dados de Sequência Molecular , beta-Lactamases/química
3.
Antimicrob Agents Chemother ; 50(7): 2403-8, 2006 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-16801418

RESUMO

The clinical strain Escherichia coli TO799 was resistant to penicillin-clavulanate combinations and ceftazidime and was not reproducibly detected as an extended-spectrum beta-lactamase (ESBL) according to the standards of the Clinical Laboratory Standards Institute (CLSI; formerly NCCLS) and the national guidelines of the French Society for Microbiology (Comité de l'Antibiogramme de la Société Française de Microbiologie). A novel beta-lactamase, designated TEM-125, was responsible for this phenotype. TEM-125 harbors a complex association of mutations previously described in the ESBL TEM-12 and in the inhibitor-resistant beta-lactamase TEM-39. TEM-125 is the first complex mutant TEM to present hydrolytic activity against ceftazidime (kcat, 3.7 s(-1)) together with a high level of resistance to clavulanate (50% inhibitory concentration, 13.6 microM). The discovery of such an ESBL, which is difficult to detect by the usual ESBL detection methods, confirms the emergence of a complex mutant TEM subgroup and highlights the need to evaluate detection methods so as to avoid possible therapeutic failures.


Assuntos
Combinação Amoxicilina e Clavulanato de Potássio/farmacologia , Antibacterianos/farmacologia , Ceftazidima/farmacologia , Escherichia coli/efeitos dos fármacos , Resistência beta-Lactâmica , beta-Lactamases/classificação , beta-Lactamases/metabolismo , Substituição de Aminoácidos , Escherichia coli/enzimologia , Escherichia coli/isolamento & purificação , Humanos , Focalização Isoelétrica , Testes de Sensibilidade Microbiana/métodos , Dados de Sequência Molecular , Reação em Cadeia da Polimerase , Análise de Sequência de DNA , beta-Lactamases/genética
4.
J Clin Microbiol ; 42(8): 3805-8, 2004 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-15297534

RESUMO

In 2002, 80 isolates of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) were collected from infected patients in our hospital. Enterobacter aerogenes was the most common bacterium isolated from all specimens (36.5%). The ESBLs were predominantly (90%) TEM derivatives (TEM-24, TEM-3). Pulsed-field gel electrophoresis highlighted that E. aerogenes, Klebsiella pneumoniae, and Citrobacter koseri had a clonal propagation.


Assuntos
Infecções por Enterobacteriaceae/epidemiologia , Enterobacteriaceae/isolamento & purificação , beta-Lactamases/metabolismo , Enterobacteriaceae/classificação , Enterobacteriaceae/enzimologia , Enterobacteriaceae/genética , França/epidemiologia , Humanos , Pacientes Internados/estatística & dados numéricos , Epidemiologia Molecular/métodos , Filogenia
5.
Antimicrob Agents Chemother ; 46(10): 3316-9, 2002 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-12234870

RESUMO

Extensive biochemical testing and 16S rRNA and rpoB sequence analysis revealed that clinical strain CF01Ent1, initially identified as Buttiauxella agrestis by the use of Api 32 biochemical strips, is a new organism in the Enterobacteriaceae family. It produced an inducible AmpC-type beta-lactamase whose sequence shares 69 to 72% identity with those of the other AmpC-type beta-lactamases of ENTEROBACTERIACEAE: This enzyme exhibits an atypical high affinity for all beta-lactams tested.


Assuntos
Enterobacteriaceae/classificação , Enterobacteriaceae/enzimologia , beta-Lactamases/biossíntese , Sequência de Aminoácidos , Antibacterianos/farmacologia , Proteínas de Bactérias/química , Proteínas de Bactérias/genética , Sequência de Bases , RNA Polimerases Dirigidas por DNA/genética , Enterobacteriaceae/efeitos dos fármacos , Enterobacteriaceae/genética , Indução Enzimática , Testes de Sensibilidade Microbiana , Dados de Sequência Molecular , RNA Ribossômico 16S/genética , Análise de Sequência de DNA , Resistência beta-Lactâmica , beta-Lactamases/química , beta-Lactamases/genética , beta-Lactamas/farmacologia
6.
Antimicrob Agents Chemother ; 46(9): 3031-4, 2002 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12183264

RESUMO

In 2000, at the Université d'Auvergne teaching hospital in Clermont-Ferrand, France, 44 (6.2%) strains of Pseudomonas aeruginosa were found to be resistant to ceftazidime. After genotyping, 34 strains were selected. Nine had an additional beta-lactamase: OXA-21 (n = 6), PSE-1 (CARB-2) (n = 2), or PER-1 (n = 1). Ceftazidime resistance was related solely to the overproduction of the cephalosporinase in 30 strains. Sequencing of five bla(AmpC) genes encoding cephalosporinases with different pIs showed 99% identity with the ampC gene of P. aeruginosa PAO1.


Assuntos
Ceftazidima/farmacologia , Cefalosporinas/farmacologia , Infecções por Pseudomonas/epidemiologia , Infecções por Pseudomonas/microbiologia , Pseudomonas aeruginosa/efeitos dos fármacos , Pseudomonas aeruginosa/enzimologia , beta-Lactamases/metabolismo , Ceftazidima/uso terapêutico , Cefalosporinase/genética , Cefalosporinase/metabolismo , Cefalosporinas/uso terapêutico , Coleta de Dados , Resistência Microbiana a Medicamentos , França/epidemiologia , Genes Bacterianos , Genótipo , Humanos , Testes de Sensibilidade Microbiana , Estudos Prospectivos , Inibidores de beta-Lactamases , beta-Lactamases/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA